Clinical trial NCT00266318 - References

Hepatitis C — Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

Citation(s)

•   Barbaro G, Barbarini G
  Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. Eur J Gastroenterol Hepatol. 2002 May;14(5
•   Buggisch P, Seegers B, Hinrichsen H, Hueppe D, Reiser M, de Heer G, et al
  2002. Combination treatment with consensus-interferon and ribavirin for chronic hepatitis C patients with non-response relapse to previous treatment with alpha-interferon and ribav
•   Cornberg M, Hadem J, Schuppert F, Reiser M, Schmidt H, Marschal O, et al
  2002. Retreatment of hepatitis C nonresponder patients with consensus interferon and ribavirin: a randomized controlled multicenter study. Hepatology 36(4 pt 2): 575A.
•   da Silva LC, Bassit L, Ono-Nita SK, Pinho JR, Nishiya A, Madruga CL, Carrilho FJ
  High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study. J Gastroen
•   Kaiser S, Hass H, Gregor M
  2002A. high dose induction therapy with consensus interferon and ribavirin for treatment naive patients with hepatitis C. Hepatology 36(4 pt 2): 362A.
•   Kaiser S, Hass H, gregor M
  2002B. High viral response rates in previous interferon/ribavirin nonresponder patients with chronic hepatitis C retreated with consensus interferon. Hepatology 36(4 pt 2): 358A.
•   Kaiser S, Hass H, Gregor M
  2003. Successful retreatment of Peginterferon nonresponder patients with chronic hepatitis C with high dose consensus interferon induction therapy. Gastroenterology 124(4):A214.

A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy

Details for clinical trial NCT00266318